Investigational drugs for the treatment of Covid-19
The adverse reactions of the following drugs and classes of drugs, which are under consideration or investigation for the treatment of patients with Covid-19, are searchable in Litt’s Drug Eruption & Reaction Database.
Other drugs developed before the emergence of Covid-19 (e.g. Remdesvir) are also under investigation for treating this disease, but are not yet approved by the FDA for other indications and therefore are not included in the Litt database.
Drugs
- Anakinra
- Ascorbic Acid
- Azithromycin
- Baricitinib
- BCG Vaccine
- Bevacizumab
- Chloroquine
- Colchicine
- Daclatasvir
- Darunavir
- Dexamethasone
- Eculizumab
- Emapalumab
- Famotidine
- Fingolimod
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Heparin
- Hydroxychloroquine
- Ibuprofen
- Imatinib
- Immune Globulin IV
- Interferon Beta
- Ivermectin
- Ledipasvir & Sofosbuvir
- Lopinavir
- Losartan
- Methylprednisolone
- Naproxen
- Nelfinavir
- Nitazoxanide
- Oseltamivir
- Ribavirin
- Ritonavir
- Sargramostin – see drug Granulocyte Colony-Stimulating Factor (G-CSF)
- Sarilumab
- Sildenafil
- Tenofovir Disoproxil
- Thalidomide
- Tocilizumab
- Vitamin C – see drug Ascorbic Acid
- Vitamin D – see drug Ergocalciferol
- Zinc